"Study of E7438 (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas (AN: NCT01897571)", Clinical Trials Gov., 27 March 2014 (2014-03-27), pages 1-8, XP055247664, Retrieved from the Internet: URL:https://clinicaltrials.gov/archive/NCT 01897571/2014_03_27 [retrieved on 2016-02-04] (B1)

'View ofNCT01897571 on 2014_03_27 on ClinicalTrials.gov Archive. Study of E7438 (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas.', [Online] 27 March 2014, XP055247664 Retrieved from the Internet: <URL:https://clinicaltrials.gov/archive/NCT Ot897571/2014_03_27> [retrieved on 2015-07-09] (B1)

DYER, MJS ET AL.: 'A New Human B- Cell Non-Hodgkin's Lymphoma Cell Line (Karpas 422) Exhibiting Both t(14; 18) and t(4;11) Chromosomal Transolcations.' BLOOD vol. 75, 1990, pages 709 - 714, XP055247666 (B1)

HASSAN, U ET AL.: 'Prognostic Sub-Grouping of Diffuse Large B- Cell Lymphomas into Germinal Centre And Post Germinal Centre Groups by Immunohistochemistry after 6 Cycles of Chemotherapy.' ASIAN PACIFIC JOURNAL OF CANCER PREVENTION. vol. 13, 2012, pages 1341 - 1347, XP055247670 (B1)

KNUTSON, SK ET AL.: 'Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma.' MOLECULAR CANCER THERAPEUTICS vol. 13, 21 February 2014, pages 842 - 854, XP055247668 (B1)

WO-A2-2014/062720 (B1)

US-A1- 2013 303 555 (B1)

WO-A1-2013/138361 (B1)

WO-A1-2014/071109 (B1)

WO-A1-2014/194254 (B1)

S. K. KNUTSON ET AL: "Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma", MOLECULAR CANCER THERAPEUTICS, vol. 13, no. 4, 1 April 2014 (2014-04-01), pages 842-854, XP055247668, US ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-13-0773 (B1)